. home.aspx

NEWS

home.aspx
   


Pfizer, Astellas' Xtandi racks up more data for new prostate cancer approval

June 02, 2019 / Carly Helfand
SHARESHARESHARE

Pfizer and Astellas’ Xtandi is gunning for a new indication in prostate cancer, and they say Sunday's new data complement the supporting evidence they’ve already generated. Sunday at the American Society of Clinical Oncology annual meeting, researchers trumpeted datafrom an investigator-sponsored study in metastatic hormone-sensitive prostate cancer (mHSPC). The study showed Xtandi slashed the risk of death by 33% compared with other non-steroidal androgen-fighting drugs. Eighty percent of men taking the Pfizer-Astellas drug were alive after three years compared with 72% of men who received the hormone-based chemo drugs bicalutamide, nilutamide or flutamide alongside standard treatment.The results from the phase 3 study, dubbed Enzamet and led by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group, back up the companies’ own results from the phase 3 Arches trial. “The two studies actually are complementary of one another,” said A...